Ets2 and mesp1 generate cardiac progenitors from fibroblasts
AssigneesUniversity of Houston, The Texas A&M University System, Texas Heart Institute
InventorsRobert J. Schwartz, Vladimir N. Potaman, Jose Francisco Islas
Life of this patent
Estimating the term…
Abstract
A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mesp1.
Claims13
A cardiac progenitor cell induced by reprogramming of a somatic cell, wherein reprogramming comprises delivery of a reprogramming factor comprising the ETS2 gene to the somatic cell.
10-14. (canceled)
An induced cardiac cell obtained by a method comprising the steps of:
- (a) transducing a somatic cell with an ETS2 reprogramming factor forming an ETS2 treated cell, wherein the ETS2 treated cell produces a pluripotent stem cell marker protein not present in the somatic cell;
- and
- (b) transducing the ETS2 treated cell with a Mesp1 reprogramming factor forming a cardiac progenitor cell, wherein the cardiac progenitor cell produces a cardiac cell marker protein neither expressed in the somatic cell nor in the ETS2 treated cell;
- wherein the somatic cell is a normal human dermal fibroblast cell.
(canceled)
Dependencies are inferred from the claim text.